Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Isaac Corro Ramos; Matthijs Versteegh; JM Koenders; GC Linssen; JG Meeder; Maureen Rutten - van Molken

doi:10.1016/j.jval.2017.05.013

Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

Isaac Corro Ramos, Matthijs Versteegh, JM Koenders, GC Linssen, JG Meeder, Maureen Rutten - van Molken

Health Technology Assessment (HTA)

Research output: Contribution to journal › Article › Academic

33 Citations (Scopus)

Original language	English
Journal	Value in Health
DOIs	https://doi.org/10.1016/j.jval.2017.05.013
Publication status	Published - 31 Jul 2017

Research programs

EMC NIHES-05-63-02 Quality

Access to Document

10.1016/j.jval.2017.05.013

http://hdl.handle.net/1765/100610

Cite this

Corro Ramos, I., Versteegh, M., Koenders, JM., Linssen, GC., Meeder, JG., & Rutten - van Molken, M. (2017). Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health. https://doi.org/10.1016/j.jval.2017.05.013

@article{64523337e584449d824c7dc540357728,

title = "Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines",

author = "{Corro Ramos}, Isaac and Matthijs Versteegh and JM Koenders and GC Linssen and JG Meeder and {Rutten - van Molken}, Maureen",

year = "2017",

month = jul,

day = "31",

doi = "10.1016/j.jval.2017.05.013",

language = "English",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

}

Corro Ramos, I, Versteegh, M, Koenders, JM, Linssen, GC, Meeder, JG & Rutten - van Molken, M 2017, 'Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines', Value in Health. https://doi.org/10.1016/j.jval.2017.05.013

Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. / Corro Ramos, Isaac; Versteegh, Matthijs; Koenders, JM et al.
In: Value in Health, 31.07.2017.

Research output: Contribution to journal › Article › Academic

TY - JOUR

T1 - Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines

AU - Corro Ramos, Isaac

AU - Versteegh, Matthijs

AU - Koenders, JM

AU - Linssen, GC

AU - Meeder, JG

AU - Rutten - van Molken, Maureen

PY - 2017/7/31

Y1 - 2017/7/31

U2 - 10.1016/j.jval.2017.05.013

DO - 10.1016/j.jval.2017.05.013

M3 - Article

C2 - 29241885

SN - 1098-3015

JO - Value in Health

JF - Value in Health

ER -

Corro Ramos I, Versteegh M, Koenders JM, Linssen GC, Meeder JG, Rutten - van Molken M. Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines. Value in Health. 2017 Jul 31. doi: 10.1016/j.jval.2017.05.013